In Vitro & In Vivo Diagnostic Substances stocks: intrinsic value, ROIC & growth
17 U.S. in vitro & in vivo diagnostic substances companies with at least three years of SEC filings, ranked by size. 4 of the 9 with a current price trade below their Graham intrinsic value. The median company earned a -11.5% average return on invested capital and grew revenue 12.5% a year.
Updated October 18, 2026
17companies
4below Graham value
-11.5%median 10-yr ROIC
12.5%median revenue CAGR
Most undervalued in vitro & in vivo diagnostic substances stocks
| Ticker | Company | Upside | Price | Graham value | Price vs value | Market cap | ROIC (10y) | Revenue CAGR |
|---|---|---|---|---|---|---|---|---|
| LNTH | Lantheus Holdings, Inc. | +14% | $99.70 | $113.27 | 12% below | $6.8B | 23.5% | 19.9% |
Highest-ROIC in vitro & in vivo diagnostic substances stocks
| Ticker | Company | 10-yr ROIC | Price | Graham value | Price vs value | Market cap | ROIC (10y) | Revenue CAGR |
|---|---|---|---|---|---|---|---|---|
| IDXX | Idexx Laboratories | 64.2% | $560.36 | $434.46 | 29% above | $45.4B | 64.2% | 10.3% |
| LNTH | Lantheus Holdings, Inc. | 23.5% | $99.70 | $113.27 | 12% below | $6.8B | 23.5% | 19.9% |
| NEOG | NEOGEN CORP | 2.4% | $11.81 | $9.51 | 24% above | $2.6B | 2.4% | 10.2% |
All in vitro & in vivo diagnostic substances stocks
| Ticker | Company | Price | Graham value | Price vs value | Market cap | ROIC (10y) | Revenue CAGR |
|---|---|---|---|---|---|---|---|
| IDXX | Idexx Laboratories | $560.36 | $434.46 | 29% above | $45.4B | 64.2% | 10.3% |
| LNTH | Lantheus Holdings, Inc. | $99.70 | $113.27 | 12% below | $6.8B | 23.5% | 19.9% |
| NEOG | NEOGEN CORP | $11.81 | $9.51 | 24% above | $2.6B | 2.4% | 10.2% |
| CLDX | Celldex Therapeutics, Inc. | $27.53 | $73.42 | 63% below | $1.8B | -46.8% | -15.2% |
| NTLA | Intellia Therapeutics, Inc. | $11.42 | — | — | $1.2B | -42.3% | 17.0% |
| QDEL | QuidelOrtho Corp | $12.91 | $495.27 | 97% below | $875.3M | 3.4% | 13.2% |
| TKNO | Alpha Teknova, Inc. | $7.08 | $2.64 | 168% above | $378.7M | -22.6% | 5.3% |
| MYGN | MYRIAD GENETICS INC | $3.98 | $0.56 | 611% above | $368.5M | -11.5% | 1.2% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $6.38 | — | — | $278.1M | -116.1% | — |
| ICCC | IMMUCELL CORP /DE/ | $10.75 | $3.48 | 209% above | $97.0M | -3.1% | 12.5% |
| IMDX | Insight Molecular Diagnostics Inc. | $3.01 | — | — | $91.7M | -102.4% | 27.2% |
| VNRX | VOLITIONRX LTD | $0.18 | — | — | $19.2M | 6599.2% | 115.8% |
| AWHL | Aspira Women's Health Inc. | $0.23 | — | — | $7.8M | 2471.6% | 14.9% |
| BMRA | BIOMERICA INC | $1.85 | — | — | $4.2M | -102.5% | 0.4% |
| CDIO | Cardio Diagnostics Holdings, Inc. | $1.69 | — | — | $3.0M | -156.0% | 101.4% |
| QCLS | Q/C TECHNOLOGIES, INC. | $0.54 | $219.51 | 100% below | $931.1K | -107.0% | -18.9% |
| BZYR | BURZYNSKI RESEARCH INSTITUTE INC | $0.00 | — | — | $26.3K | 3995.0% | — |
Stock lists
Undervalued Stocks Below Graham Intrinsic Value
Highest ROIC Stocks (10-Year Average)
Highest Free Cash Flow Yield Stocks
Fastest-Growing Stocks by 10-Year Revenue